Zhiming Li

机构：Sun Yat-sen University, Shandong Tumor Hospital, Sun Yat-sen University Cancer Center, Shandong First Medical University · ORCID：0000-0002-9419-0479

发表论文 22 篇 · 总被引 542 次 · h-index 11

代表论文

• Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China (2017 · Journal of Hematology & Oncology · 被引 259)
• MYD88 somatic mutations in MALT lymphomas (2012 · British Journal of Haematology · 被引 46)
• Review on natural killer/T‐cell lymphoma (2021 · Hematological Oncology · 被引 43)
• First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Haematology · 被引 33)
• A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China (2021 · Frontiers in Oncology · 被引 22)
• Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma (2023 · Cell Reports Medicine · 被引 21)